Online citations, reference lists, and bibliographies.
← Back to Search

[Conversion Ratio Between Different Botulinum Neuroprotein Product In Neurological Practice].

O. Orlova, S. Timerbaeva, S. Khatkova, E. Kostenko, D. A. Krasavina, D. Zakharov
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Despite nearly 30 years of experience in the application of botulinum toxin type A (BTA) in clinical practice, many fundamental questions of therapy remain valid. There are 5 botulinum toxin type A used for neurological indications in the Russian Federation in 2017. They contain different number of active neuroprotein (150 kDa) in a therapeutic dose of the drug that may have a potential impact on the efficacy and duration of action. The current SmPC of each BTA stated that the unit of activity is unique and can not be compared with any other BTA. In scientific publications one can find many details concerning the equivalence doses of onabotulinumtoxin A (botox) and abobotulinumtoxin A (dysport) and the ratio of units varies from 1:1 to 1:11. However, according to clinical guidelines, systematic reviews and high quality research evidence of recent years, the ratio of units of abobotulinumtoxin A (dysport) and onabotulinumtoxin A (botox) is 3(2,5):1. Use of a fixed ratio of units is possible only when switching from one drug to another or in case of limiting access to specific drug. Botulinum toxin type A is the first line of therapy in the treatment of several neurological diseases. The most commonly used drugs of botulinum toxin type A (botox, dysport, xeomin) have a significant evidence base that confirms their efficacy and optimal safety profile. The main difference between botulinum toxin type A is their potential activity of action, i.e., activity units and total therapeutic dose.
This paper references
Dose standardization of botulinum toxin.
P. V. D. van den Bergh (1998)
Studies on the dissociation of botulinum neurotoxin type A complexes.
Karl-Heinz Eisele (2011)
Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids
R. Kassir (2013)
Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers
K. Wohlfarth (2009)
Duration of action of abobotulinumtoxina and onabotulinumtoxina: a randomized, double-blind study using a contralateral frontalis model.
M. Nestor (2011)
A Randomized Double-Blind Study of the Effect of Botox and Dysport/Reloxin on Forehead Wrinkles and Electromyographic Activity
K. Fosse (2007)
Botulinum toxin assessment , intervention and aftercare for lower limb spasticity in children with cerebral palsy : international consensus statement
S. C. Lovea (2010)
European consensus table on the use of botulinum toxin type A in adult spasticity.
J. Wissel (2009)
Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products
J. Frevert (2015)
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
J. Park (2011)
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
Current Evidence on the Unit Equivalence of Different Botulinum Neurotoxin A Formulations and Recommendations for Clinical Practice in Dermatology
S. Karsai (2009)
Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
D. Hexsel (2012)
Botulinum toxin assessment, intervention and after‐care for lower limb spasticity in children with cerebral palsy: international consensus statement
S. Love (2010)
A long-term follow-up of botulinum toxin A in cervical dystonia
B. Mohammadi (2009)
Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?
K. Wohlfarth (2009)
Clinical comparability of marketed formulations of botulinum toxin
C. Sampaio (2004)
Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review
J. Cohen (2017)
Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and EnergyBased Devices. Dermatol Surg
J. Carruthers (2016)
A Review of AbobotulinumtoxinA (Dysport) Aesthetic Surgery Journal
Foad Nahai (2013)
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache
D. Simpson (2016)
The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
M. Wortzman (2009)
A review of AbobotulinumtoxinA (Dysport).
Z. P. Lorenc (2013)
OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review
K. Dashtipour (2016)
Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices
J. Carruthers (2016)
Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
M. Brin (2008)
Spasticity in adults: management using botulinum toxin: National Guidelines.
S. Ashford (2009)
Recovery from botulinum neurotoxin poisoning in vivo
J. Keller (2006)
Abo‐, Inco‐, Ona‐, and Rima‐Botulinum Toxins in Clinical Therapy: A Primer
J. Chen (2013)
Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence
R. Ravenni (2013)
Clinical Relevance of Botulinum Toxin Immunogenicity
R. Benecke (2012)
Botulinum Toxin Therapy for Cervical Dystonia: The Science of Dosing
V. Evidente (2014)
Р . Возможности и перспективы использования ботулоток - сина в клинической практике
О. Орлова (2013)
A Randomized Pilot Study Comparing the Action Halos of Two Commercial Preparations of Botulinum Toxin Type A
D. Hexsel (2008)
Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg
L. Carli (2009)
Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics: Targets and Therapy
MF Brin (2014)
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
F. Scaglione (2016)
Current aesthetic use of abobotulinumtoxinA in clinical practice: an evidence-based consensus review.
C. Maas (2012)
Botulinum toxin type A products are not interchangeable: a review of the evidence
M. Brin (2014)
Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
J. Frevert (2010)
Onabotulinumtoxin A and Abobotulinumtoxin A Dose Conversion: a Systematic Literature Review
K. Dashtipour (2016)
Vozh - mozhnosti I perspective ispol ’ zovaniya botuloksina v klinicheskoj praktike
OR Orlova (2006)
Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis
M. Fabbri (2015)
Pharmacology of botulinum toxin: differences between type A preparations
R. Rosales (2006)
Do different formulations of botulinum toxin type A really have different migration characteristics?
S. Karsai (2008)
Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them.
M. Hallett (2015)
Возможности и перспективы педагогического моделирования как одного из направлений современного педагогического поиска
Дементьева Инга Валерьевна (2013)
Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study
A. Marchetti (2005)
A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity.
S. Karsai (2007)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar